[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer of Rocket Pharmaceuticals, Inc. (RCKT), reported a sale of 11,161 shares of common stock on 08/14/2025 at a reported price of $3.019 per share. The Form 4 shows Schwartz held 224,094 shares following the transaction. The filing states the sold shares were disposed to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units that convert one-for-one into common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/18/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer di Rocket Pharmaceuticals, Inc. (RCKT), ha dichiarato la vendita di 11.161 azioni ordinarie il 08/14/2025 a un prezzo riportato di $3.019 per azione. Il Modulo 4 indica che dopo l'operazione Schwartz deteneva 224.094 azioni. La comunicazione specifica che le azioni vendute sono state cedute per soddisfare obblighi fiscali derivanti dalla maturazione di Restricted Stock Units che si convertono una a una in azioni ordinarie. Il Modulo 4 猫 stato sottoscritto da un procuratore in nome della persona segnalante il 08/18/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer de Rocket Pharmaceuticals, Inc. (RCKT), inform贸 la venta de 11.161 acciones ordinarias el 08/14/2025 a un precio reportado de $3.019 por acci贸n. El Formulario 4 muestra que tras la operaci贸n Schwartz pose铆a 224.094 acciones. La presentaci贸n indica que las acciones vendidas se dispusieron para cubrir obligaciones fiscales vinculadas a la adquisici贸n de Restricted Stock Units que se convierten una a una en acciones ordinarias. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante el 08/18/2025.
Jonathan David Schwartz, Rocket Pharmaceuticals, Inc. (RCKT)鞚� Chief Medical & Gene Therapy Officer電� 08/14/2025鞐� 氤错喌欤� 11,161欤茧ゼ 欤茧嫻 $3.019搿� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 瓯半灅 頉� Schwartz臧� 224,094欤茧ゼ 氤挫湢頃橁碃 鞛堧崢 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 毵る弰霅� 欤检嫕鞚� Restricted Stock Units鞚� 甓岆Μ 頇曥爼(1雽�1搿� 氤错喌欤茧 鞝勴櫂)鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 觳橂秳霅� 瓴冹瀰雼堧嫟. Form 4電� 08/18/2025鞐� 氤搓碃鞚胳潉 雽�鞁犿暣 雽�毽秾鞚� 臧�歆� 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer de Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 la vente de 11 161 actions ordinaires le 08/14/2025 au prix d茅clar茅 de 3,019 $ par action. Le formulaire 4 indique que Schwartz d茅tenait 224 094 actions apr猫s la transaction. Le d茅p么t pr茅cise que les actions vendues ont 茅t茅 c茅d茅es pour satisfaire des obligations fiscales li茅es 脿 la lev茅e de Restricted Stock Units qui se convertissent une pour une en actions ordinaires. Le formulaire 4 a 茅t茅 sign茅 au nom de la personne d茅clarante par un mandataire le 08/18/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer von Rocket Pharmaceuticals, Inc. (RCKT), meldete am 08/14/2025 den Verkauf von 11.161 Stammaktien zu einem gemeldeten Preis von $3.019 je Aktie. Im Formular 4 ist vermerkt, dass Schwartz nach der Transaktion 224.094 Aktien hielt. In der Meldung hei脽t es, die verkauften Aktien seien zur Erf眉llung steuerlicher Einbehaltspflichten im Zusammenhang mit der Vesting von Restricted Stock Units ver盲u脽ert worden, die sich eins zu eins in Stammaktien wandeln. Das Formular 4 wurde am 08/18/2025 von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.
- None.
- None.
Insights
TL;DR: A routine insider sale of vested RSU shares to cover taxes; not a material change to ownership.
The transaction is explicitly described as a sale to satisfy tax withholding upon RSU vesting, indicating a non-discretionary, administrative sale rather than an opportunistic divestiture. The number sold, 11,161 shares, reduced post-transaction holdings to 224,094 shares. For investors, this action signals routine compensation mechanics and continued substantial ownership by the reporting person. No options, derivative transactions, or new grants are reported in this Form 4.
TL;DR: Filing demonstrates compliance with Section 16 reporting and documents tax-related disposition of vested RSUs.
The Form 4 discloses the nature of the disposition and includes the reporter's title and the attorney-in-fact signature, meeting disclosure formalities. The explicit remark that shares were sold to pay tax withholding obligations clarifies the intent and supports customary insider reporting practices. There is no indication of unusual timing or related-party transactions in this filing.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer di Rocket Pharmaceuticals, Inc. (RCKT), ha dichiarato la vendita di 11.161 azioni ordinarie il 08/14/2025 a un prezzo riportato di $3.019 per azione. Il Modulo 4 indica che dopo l'operazione Schwartz deteneva 224.094 azioni. La comunicazione specifica che le azioni vendute sono state cedute per soddisfare obblighi fiscali derivanti dalla maturazione di Restricted Stock Units che si convertono una a una in azioni ordinarie. Il Modulo 4 猫 stato sottoscritto da un procuratore in nome della persona segnalante il 08/18/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer de Rocket Pharmaceuticals, Inc. (RCKT), inform贸 la venta de 11.161 acciones ordinarias el 08/14/2025 a un precio reportado de $3.019 por acci贸n. El Formulario 4 muestra que tras la operaci贸n Schwartz pose铆a 224.094 acciones. La presentaci贸n indica que las acciones vendidas se dispusieron para cubrir obligaciones fiscales vinculadas a la adquisici贸n de Restricted Stock Units que se convierten una a una en acciones ordinarias. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante el 08/18/2025.
Jonathan David Schwartz, Rocket Pharmaceuticals, Inc. (RCKT)鞚� Chief Medical & Gene Therapy Officer電� 08/14/2025鞐� 氤错喌欤� 11,161欤茧ゼ 欤茧嫻 $3.019搿� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 瓯半灅 頉� Schwartz臧� 224,094欤茧ゼ 氤挫湢頃橁碃 鞛堧崢 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 毵る弰霅� 欤检嫕鞚� Restricted Stock Units鞚� 甓岆Μ 頇曥爼(1雽�1搿� 氤错喌欤茧 鞝勴櫂)鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 觳橂秳霅� 瓴冹瀰雼堧嫟. Form 4電� 08/18/2025鞐� 氤搓碃鞚胳潉 雽�鞁犿暣 雽�毽秾鞚� 臧�歆� 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer de Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 la vente de 11 161 actions ordinaires le 08/14/2025 au prix d茅clar茅 de 3,019 $ par action. Le formulaire 4 indique que Schwartz d茅tenait 224 094 actions apr猫s la transaction. Le d茅p么t pr茅cise que les actions vendues ont 茅t茅 c茅d茅es pour satisfaire des obligations fiscales li茅es 脿 la lev茅e de Restricted Stock Units qui se convertissent une pour une en actions ordinaires. Le formulaire 4 a 茅t茅 sign茅 au nom de la personne d茅clarante par un mandataire le 08/18/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer von Rocket Pharmaceuticals, Inc. (RCKT), meldete am 08/14/2025 den Verkauf von 11.161 Stammaktien zu einem gemeldeten Preis von $3.019 je Aktie. Im Formular 4 ist vermerkt, dass Schwartz nach der Transaktion 224.094 Aktien hielt. In der Meldung hei脽t es, die verkauften Aktien seien zur Erf眉llung steuerlicher Einbehaltspflichten im Zusammenhang mit der Vesting von Restricted Stock Units ver盲u脽ert worden, die sich eins zu eins in Stammaktien wandeln. Das Formular 4 wurde am 08/18/2025 von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.
FAQ
What did Jonathan David Schwartz report on Form 4 for RCKT?
Why were the 11,161 RCKT shares sold by the reporting person?
How many RCKT shares does Jonathan David Schwartz own after the transaction?
What is Jonathan David Schwartz鈥檚 role at Rocket Pharmaceuticals?
When was the Form 4 signed and who signed it?
